Protection gonadique contre les effets des chimiothérapies et/ou radiothérapies chez l'homme: applications cliniques

This publication has 11 references indexed in Scilit:

• Treatment with the Gonadotropin-Releasinghormone Agonist Buserelin to Protect Spermatogenesis against Cytotoxic Treatment in Young Men/Behandlung zum Schutz der Spermatogenese bei cytotoxischer Therapie mit dem Gonadotropin-Hormon Agonisten Buserelin
  Andrologia, 2009
• Protection gonadique contre les effets iatrogènes des traitements anticancéreux: données expérimentales
  Andrologie, 1995
• Protective effect of medroxyprogesterone acetate plus testosterone against radiation-induced damage to the reproductive function of male rats and their offspring.
  Proceedings of the National Academy of Sciences, 1991
• Reproductive Toxicity with and without LHRH_AAdministration During Adjuvant Chemotherapy in Patients with Germ Cell Tumors
  Hormone and Metabolic Research, 1990
• Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?
  Medical and Pediatric Oncology, 1989
• Lack of Gonadal Protection by Medroxyprogesterone Acetate‐induced Transient Medical Castration during Chemotherapy for Testicular Cancer
  British Journal of Urology, 1988
• Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations
  Blood, 1985
• Scrotal Hypothermia and the Infertile Man
  Journal of Urology, 1984
• High rate of long‐term survivals in aml treated by chemotherapy and androgenotherapy. A pilot study
  Cancer, 1980
• Control of Human Spermatogenesis Intrascrotal Temperature
  Published by American Medical Association (AMA) ,1968